Title of Study:
COMPASS-2: Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)
Description:
This study will investigate the effects of the combination of bosentan and sildenafil. This approach appears as a highly attractive therapeutic option to address the multiple pathophysiological mechanisms that are present in PAH. Several advantages are obvious: both substances are orally available and both are usually well tolerated. In addition, bosentan and sildenafil have different mechanisms of action, aiming at different intracellular targets. This implies that combination therapy is likely to result in synergistic effects. It will be the first event-driven study in PAH ever conducted. The dual treatment with bosentan and sildenafil might further prevent or reverse vasoconstriction, thrombosis and changes in vascular structure, thus ultimately improving the prognosis of PAH patients.
Contact:
Website for more information and study sites
Study End Date:
Expected June 2010
Study Sponsor:
Actelion Pharmaceuticals
